Huilai X. Zhang
Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 223 publications
Neoplastic CD3⁺ B cells remodel the DLBCL tumor microenvironment via single-cell and spatial transcriptomics.
Journal: Cancer biology & therapy
Published: June 05, 2026
Extranodal involvement defines distinct immune-molecular phenotypes and clinical outcomes in diffuse large b-cell lymphoma.
Journal: Clinical and experimental medicine
Published: May 25, 2026
Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 13, 2026
Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1-3a follicular lymphoma.
Journal: Frontiers in immunology
Published: April 30, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 16, 2026
Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.
Journal: American journal of hematology
Published: February 06, 2026
Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.
Journal: Frontiers in immunology
Published: January 18, 2026
CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma.
Journal: Lancet (London, England)
Published: November 10, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.
Journal: Cancer biology & medicine
Published: September 30, 2025
Last Updated: 09/26/2026